Roche preps filings for satralizumab in rare disease NMOSD

Who will be the biggest pharma players in orphan drugs?

New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with Roche coming out in the lead.

After epilepsy setback, Zogenix buys Modis and rare disease ...

Zogenix has bounced back from the FDA’s rejection of its only drug, with the acquisition of Modis Therapeutics and a developmental rare disease drug that has already been championed by regu

Rhythm doesn’t miss a beat as obesity drug clears phase 3 te...

Daiichi Sankyo’s pexidartinib is first FDA-approved drug for...

/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0;

Vertex presses go on its cystic fibrosis triple filing